---
title: "Tremfya (guselkumab) in plaque psoriasis: Specific populations questions"
description: "Specific populations questions on Tremfya (guselkumab) in plaque psoriasis, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Pediatric use. Questions: Is Tremfya approved for children with plaque psoriasis? What are Tremfya side effects in children with plaque psoriasis? 2 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/tremfya--plaque-psoriasis/specific-populations"
published: "2026-11-13T03:43:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Tremfya (guselkumab) in plaque psoriasis: Specific populations questions

Manufacturer: Janssen Biotech, Inc.  
Prescribing information: [Tremfya](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TREMFYA-pi.pdf)

Specific populations questions that apply to every indication of Tremfya are on [Tremfya (guselkumab), all indications: Specific populations](https://www.evicenter.com/medical-information/tremfya/specific-populations).

## Pediatric use

<a id="tremfya-pediatric-approval"></a>

### Is Tremfya approved for children with plaque psoriasis?

Applies to: Moderate to severe plaque psoriasis in pediatric patients 6 years of age and older who are candidates for systemic therapy or phototherapy

> “TREMFYA<sup>®</sup> (guselkumab) is indicated for the treatment of adults and pediatric patients 6 years of age and older who also weigh at least 40 kg with moderate to severe plaque psoriasis and who are candidates for systemic therapy or phototherapy.”

Source: [TREMFYA: Moderate To Severe Pediatric Plaque PsO, captured 2026-11-13](https://www.tremfyahcp.com/plaque-psoriasis/pediatric/#:~:text=%28guselkumab%29%20is%20indicated%20for%20the,for%20systemic%20therapy%20or%20phototherapy.)

> “The safety and effectiveness of TREMFYA for the treatment of moderate-to- 
> severe plaque psoriasis have been established in pediatric patients 6 years of age 
> and older who are candidates for systemic therapy or phototherapy [see Adverse 
> Reactions (6.1) and Clinical Studies (14.1)].
> The safety and effectiveness of TREMFYA have not been established in pediatric 
> patients with plaque psoriasis who are younger than 6 years of age.”

Source: [TREMFYA: Prescribing information, page 5, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TREMFYA-pi.pdf#page=5)

<a id="tremfya-pediatric-side-effects"></a>

### What are Tremfya side effects in children with plaque psoriasis?

Applies to: Moderate to severe plaque psoriasis in pediatric patients 6 years of age and older who are candidates for systemic therapy or phototherapy

> “The safety of TREMFYA was studied in one placebo- and active-controlled clinical 
> trial (PsO5) that included 120 pediatric subjects 6 years of age and older with 
> moderate-to-severe plaque psoriasis [see Clinical Studies (14.1)]. The safety profile 
> observed in pediatric subjects 6 years of age and older treated with TREMFYA up 
> to 52 weeks was consistent with the safety profile observed in adult subjects with 
> moderate-to-severe plaque psoriasis.”

Source: [TREMFYA: Prescribing information, page 3, captured 2026-11-13](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TREMFYA-pi.pdf#page=3)

## Related pages
- [Medical information: Tremfya (guselkumab): Plaque psoriasis](https://www.evicenter.com/medical-information/tremfya--plaque-psoriasis)
- [Indication](https://www.evicenter.com/medical-information/tremfya--plaque-psoriasis/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/tremfya--plaque-psoriasis/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/tremfya--plaque-psoriasis/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/tremfya--plaque-psoriasis/safety)
- [Dosing and administration](https://www.evicenter.com/medical-information/tremfya--plaque-psoriasis/dosing-and-administration)
- [Access and coverage](https://www.evicenter.com/medical-information/tremfya--plaque-psoriasis/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/tremfya--plaque-psoriasis/guidelines)
